1. Most Discussed
  2. Gainers & Losers
PBI 0.0¢

resmed shakes off us action

  1. ResMed shakes off US action


    September 9, 2003

    SLEEP diagnostics technology maker ResMed has settled two patent infringement lawsuits with US rival Respironics but kept its forecasts unchanged.


    The settlement, the terms and conditions of which are confidential, resolved matters stemming back to a 1995 action in Pennsylvania and a 2002 action in California, both brought by ResMed.

    ResMed claimed Respironics, whose strong sales growth last year prompted concerns about ResMed's growth prospects and a slump in its share price, infringed its patents.


    "ResMed and Respironics will dismiss all lawsuits with prejudice," the companies said in a joint statement.


    "Neither company is changing its financial guidance or outlook for fiscal year 2004 based on the settlement."


    Last month, ResMed reported 2002/03 profit up 22 per cent to $US45.729 million ($70.88 million), helped in part by a one-off boost from SARS-related sales in the fourth quarter.


    Today, ResMed chairman and chief executive Peter Farrell said the resolution would allow the company to increase its research and development, and "awareness efforts" focused on the treatment of undiagnosed sleep disordered breathing.


    Respironics chief executive Jim Liken said the settlement was positive "for our company and the industry".


    ResMed settled a separate dispute with Fisher & Paykel Healthcare Corp Ltd in May this year.

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top